^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) + Reolysin (pelareorep) (Apoptosis stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.
Published date:
05/25/2023
Excerpt:
This is a randomized phase 2 study in pts with HR+/HER2- metastatic breast cancer….After a safety run-in for Cohort 3, patients were randomized 1:1:1 to PTX-alone (Cohort 1), PTX + pelareorep (Cohort 2), or PTX + pelareorep + avelumab (Cohort 3)….The addition of pelareorep to PTX is an active regimen with a high 6-month PFS rate...
DOI:
10.1200/JCO.2023.41.16_suppl.1012
Trial ID:
